Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT01046110
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 458 participants
- Sponsor
- Registry
-
NCT01046110
-
- Other papers using this trial's data
- Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, India, Mexico, South Africa, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01046110. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2015-11-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01046110- Content hash
e8053ee9e65ad6f37926d5f428a11dc9c6e83bc373d9aa52b6205d1aa037ad72